...
首页> 外文期刊>Japanese Journal of Pharmacology >Thrombolysis of Canine Femoral Artery Thrombus by a Novel Modified Tissue-Type Plasminogen Activator (E6010)
【24h】

Thrombolysis of Canine Femoral Artery Thrombus by a Novel Modified Tissue-Type Plasminogen Activator (E6010)

机译:新型改良的组织型纤溶酶原激活剂(E6010)对犬股动脉血栓的溶栓作用

获取原文
           

摘要

References(29) Cited-By(2) The thrombolytic activity of a novel modified tissue-type plasminogen activator (t-PA) (E6010) was examined in a canine model with copper coil-induced femoral artery thrombus. This model, in which thrombolytic activity can be easily and directly quantified by determining changes in thrombus weight, should be useful for comparing the activities of various thrombolytic agents. Using this model, the present study showed that the thrombolytic activity of bolus intravenous injection of E6010 was identical to that of continuous intravenous infusion of recombinant t-PA at the same dose. This thrombolytic activity can be explained by changes in blood concentrations of the administered thrombolytic agents. On the other hand, administration of the thrombolytic agents dose-dependently caused significant changes in the levels of hemostatic and fibrinolytic factors. These changes were not so marked with administration of E6010, and therefore we concluded that E6010 is unlikely to cause bleeding complications after administration
机译:参考文献(29)引用了(2)在铜线圈诱发的股动脉血栓的犬模型中,研究了新型修饰的组织型纤溶酶原激活物(t-PA)(E6010)的溶栓活性。通过确定血栓重量的变化,可以轻松,直接地量化溶栓活性的模型对于比较各种溶栓剂的活性应该是有用的。使用该模型,本研究显示推注静脉内注射E6010的溶栓活性与以相同剂量连续静脉内注射重组t-PA的溶栓活性相同。这种溶栓活性可以通过所用溶栓剂的血药浓度变化来解释。另一方面,溶栓剂的剂量依赖性地引起止血和纤溶因子水平的显着变化。这些变化在使用E6010时并没有那么明显,因此我们得出结论,E6010不太可能在给药后引起出血并发症

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号